Tresperimus

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598762

CAS#: 160677-67-8

Description: Tresperimus induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model.

Chemical Structure

img
Tresperimus
CAS# 160677-67-8
Instruction

Theoretical Analysis

MedKoo Cat#: 598762
Name: Tresperimus
CAS#: 160677-67-8
Chemical Formula: C17H37N7O3
Exact Mass: 387.30
Molecular Weight: 387.520
Elemental Analysis: C, 52.69; H, 9.62; N, 25.30; O, 12.39

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 160677-67-8 (free base)   160678-11-5 (3HCl)  

Synonym: Tresperimus; LF-08-0299; LF 08-0299; LF08-0299;

IUPAC/Chemical Name: 2-((6-guanidinohexyl)amino)-2-oxoethyl (4-((3-aminopropyl)amino)butyl)carbamate

InChi Key: LVBMFPUTQOHXQE-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H37N7O3/c18-8-7-10-21-9-5-6-13-24-17(26)27-14-15(25)22-11-3-1-2-4-12-23-16(19)20/h21H,1-14,18H2,(H,22,25)(H,24,26)(H4,19,20,23)

SMILES Code: O=C(OCC(NCCCCCCNC(N)=N)=O)NCCCCNCCCN

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 387.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bousquet E, Camelo S, Leroux les Jardins G, Goldenberg B, Naud MC, Besson-Lescure B, Lebreton L, Annat J, Behar-Cohen F, de Kozak Y. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011 Jul 20;52(8):5414-23. doi: 10.1167/iovs.10-6740. PubMed PMID: 21666239.

2: Simpson D. Tresperimus: a new agent for transplant tolerance induction. Expert Opin Investig Drugs. 2001 Jul;10(7):1381-6. Review. PubMed PMID: 11772258.

3: el Marsafy S, Dutartre P, Gluckman E. Effect of tresperimus on ex vivo expansion of CD34+CD38(-)-enriched cord blood cells. Haematologia (Budap). 2002;32(4):327-36. PubMed PMID: 12803107.

4: Claud P, Artur Y, Guichard JP, Laine R. Metabolism of tresperimus by rat aorta semicarbazide-sensitive amine oxidase (SSAO). Fundam Clin Pharmacol. 2002 Dec;16(6):461-70. PubMed PMID: 12685504.

5: Claud P, Artur Y, Laine R. In vitro metabolism of tresperimus by human vascular semicarbazide-sensitive amine oxidase. Drug Metab Dispos. 2002 Jun;30(6):747-55. PubMed PMID: 12019205.

6: El Marsafy S, Dutartre P, Gluckman E. Effect of tresperimus on in vitro human cord blood CD34+ cell differentiation. Haematologia (Budap). 2001;31(2):139-46. PubMed PMID: 11583025.

7: Claud P, Padovani P, Guichard JP, Artur Y, Lainé R. Involvement of semicarbazide-sensitive amine oxidase in tresperimus metabolism in human and in rat. Drug Metab Dispos. 2001 May;29(5):735-41. PubMed PMID: 11302941.

8: Elices MJ. Tresperimus (Laboratoires Fournier). Curr Opin Investig Drugs. 2001 Mar;2(3):372-4. PubMed PMID: 11575707.

9: Komesli S, Dumas C, Dutartre P. Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Int J Immunopharmacol. 1999 May;21(5):349-58. PubMed PMID: 10408631.

10: Annat J, Dutartre P. T cell repertoire expression in murine recipients of bone marrow transplant after LF 08-0299 (Tresperimus) administration. Transpl Immunol. 1998 Dec;6(4):217-24. PubMed PMID: 10342735.

11: Tresperimus. LF 080299. Drugs R D. 1999 Jan;1(1):110-1. PubMed PMID: 10566003.

12: Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs. 2002;62(6):879-89. Review. PubMed PMID: 11929336.

13: Simpson D. Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res. 2000 Jun;9(3):317-25. Review. PubMed PMID: 10894353.

14: Bruley-Rosset M, Churaqui E, Annat J, Dutartre P. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease. Transplant Proc. 1996 Dec;28(6):3114-6. PubMed PMID: 8962208.

15: Bruley-Rosset M, Churaqui E, Annat J, Dutartre P. LF 08-0299 protects murine recipients of minor antigen disparate donor marrow from lethal graft-versus-host disease. Ann N Y Acad Sci. 1995 Dec 29;770:373-5. PubMed PMID: 8597379.

16: Dutartre P, Annat J, Derrepas P. LF 08-0299 induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model. Transplant Proc. 1995 Feb;27(1):440-2. PubMed PMID: 7879054.

17: Andoins C, de Fornel D, Annat J, Dutartre P. Both CD45RC+ and negative CD4+ suppressor cells are present in the rat cardiac allograft LF 08-0299-induced tolerance model. Transplant Proc. 1997 Feb-Mar;29(1-2):1282-4. PubMed PMID: 9123307.

18: Simpson D. New developments in the prophylaxis and treatment of graft versus host disease. Expert Opin Pharmacother. 2001 Jul;2(7):1109-17. Review. PubMed PMID: 11583062.

19: Lácha J, Rossmann P, Lodererová A, Havlíèková J, Vítko S. LF 08-0299 in the prophylaxis and treatment of chronic rejection in a rat aortic allograft model. Transpl Int. 2000;13 Suppl 1:S565-7. PubMed PMID: 11112075.

20: Andoins C, de Fornel D, Annat J, Dutartre P. Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells. Transplantation. 1996 Dec 15;62(11):1543-9. PubMed PMID: 8970605.